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Using a treatment transition moDel to evalUate the effects of 
neglecting hBa1c Drift in oral anti-DiaBetic DrUgs for tyPe 2 
DiaBetes
Smolen H.J., Yu X.
Medical Decision Modeling Inc., Indianapolis, IN, USA
OBJECTIVES: HbA1c drift is the gradual loss of treatment efficacy typically for oral 
anti-diabetic drugs. Modeling studies including the effects of HbA1c drift in oral 
anti-diabetic drugs are rare in the literature. Clinical outcomes can be distorted if 
the drifts are not considered. Our study compared the simulated clinical outcomes 
of type 2 diabetic mellitus (T2DM) treatments with and without drift. METHODS: 
Lifetime clinical outcomes of treatments were estimated using a Monte Carlo 
microsimulation model. The simulated cohort was newly diagnosed age 45 T2DM 
patients with an initial 8.5% HbA1c level. Demographic and clinical characteristics 
were sourced from NHANES data. Two scenarios were simulated. Both scenarios 
were aligned with Vijan et al., 2014. The first scenario compared the benefit of met-
formin with and without drift over a stable HbA1c of 8.5%. The second compared 
metformin with drift to basal-bolus insulin. Drift data were extrapolated from 
clinical trials. RESULTS: Metformin treatment without drift gained 3.02 life years 
(LY), while with drift the LY gain was only 0.08. For 100,000 simulated patients, 
metformin without drift prevents 1,960 myocardial infarctions (MIs), 320 strokes, 
10,610 cases of blindness, 27,390 lower extremity amputations (LEAs), and 19,010 
end stage renal disease cases requiring dialysis (ESRDs). When HbA1c drift was 
considered, the benefits of metformin treatment shrank to no additional strokes, 
prevention of 500 cases of blindness, 700 LEAs, and 410 ESRDs, with an increase 
of 100 MIs. The direct comparison of LY of metformin with drift and insulin treat-
ment showed that the insulin gained 2.51 LY over metformin. Compared with 
metformin treatment with drift, insulin treatment prevented more complication 
events including 2,110 MIs, -140 strokes, 8,340 cases of blindness, 20,450 LEAs, and 
16,390 ESRDs. CONCLUSIONS: HbA1c drift in oral anti-diabetic drugs has substan-
tial effects on clinical outcomes and should be incorporated into diabetes health 
outcome models.
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OBJECTIVES: Type 2 Diabetes(T2D) has multiple comorbid complications. Early 
detection of T2D can delay and prevent these complications. We study the preva-
lence and timing of occurrence of complications of diabetes including cardiovas-
cular, cerebrovascular, renal, and eye complications, for patients newly-diagnosed 
with T2D. METHODS: We studied a cohort of 4.1million insurance beneficiaries 
of age≥ 18yrs with recorded claims between 2005 and 2013. Among them 26,778 
patients were newly diagnosed with T2D, and had continuous enrollment for 3-years 
prior-to- and 1-year post-T2D diagnosis. We defined diabetes complications based 
on the diabetes complications severity index. We assessed number and percentages 
of patients with each complication, in total, and in relation to time of T2D diagno-
sis. RESULTS: Among 26,778 patients newly diagnosed with T2D, 13,538 had at least 
one complication during the observation period. Of these patients, 9,526(70%) had 
it before T2D diagnosis and 1,102(8%) had it within 6months after T2D diagnosis. A 
total of 10,143 patients had cardiovascular complications during observation period. 
Of these patients, 7,338(72%) had them before T2D diagnosis, and 720(7%) had them 
within 6months after T2D diagnosis. A total of 3,686 patients had cerebrovascular 
complications during observation period. Of these patients, 2,222(60%) had them 
before T2D diagnosis, and 294(8%) had them within 6months after T2D diagnosis. A 
total of 4,358 patients had renal complications during observation period. Of these, 
2,215(50%) had them before T2D diagnosis, and 517(11%) had them within 6months 
after T2D diagnosis. A total of 2,286 patients had eye complications during study 
period. Of these patients, 928(40%) had them before T2D diagnosis, and 355(14%) had 
them within 6months after T2D diagnosis. CONCLUSIONS: In our cohort, conditions 
associated with long-term complications of diabetes were commonly diagnosed 
before or soon after T2D diagnosis date. Better approaches for early detection and 
treatment of T2D are needed, to prevent or delay its complications.
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OBJECTIVES: The literature documents that patients with diabetes have greater 
risks of developing dementia, suggesting that antidiabetic agents might lower the 
risk of dementia. However, it remains unclear about the roles of specific anti-dia-
betic drug classes in developing dementia in the elderly. Furthermore, traditional 
methodology of capturing dementia using claims data alone in observational 
studies are subject to significant underestimation of dementia. The objective 
of this study is to explore the association between specific anti-diabetic drugs 
and the risk of dementia or Alzheimer’s diseases (AD) identified by an improved 
methodology among the elderly. METHODS: A retrospective cohort study was 
conducted using data from the Medicare Current Beneficiary Survey (MCBS) 
linked to the Medicare claims from 2001 to 2010. The study sample consisted of 
Medicare beneficiaries aged> 65 years and were diagnosed with diabetes. Anti-
diabetic medications, both insulins and oral anti-diabetic agents, were identified 
from the prescription medication file. Dementia or AD was determined based 
on the patients’ self-reports, diagnosis codes in Medicare claims, or dementia-
targeted medications during 2-year follow up period to identify incident dementia. 
Multivariable logistic regressions were used to estimate the association between 
anti-diabetic drugs and dementia. Cross-sectional weights were used to adjust for 
the complex survey design. RESULTS: Overall, after adjusting for demographics, 
from 2011-2013 we selected a cohort of men diagnosed with hypogonadism 
who had no evidence of hypogonadism in a six month pre period. These men 
were divided into those who received injectable testosterone therapy (case-T) 
and those who did not (control-NT). For analysis three controls were selected for 
each case using Greedy matching on age, race, Charleson comorbidity index (CCI), 
presence of hypercholesteremia and hypertension. Each cohort was followed for 
two years identifying outcomes including: gynecomastia, abnormal weight gain, 
stroke, myocardial infarction (MI), osteopenia, and osteoporosis. Median time to 
event was calculated for each group. Kaplan-Meyer curves with Wilcoxon tests 
were used to compare time to event for each disease. RESULTS: 1625 cases were 
identified as well as 4794 Greedy matched controls. T-test and chi-square analysis 
on all matching criteria showed no difference between the two groups at base-
line. Kaplan-Meyer analysis associated testosterone therapy with delayed time in 
months to event in osteoporosis (T= 7 months, NT= 4 months, p= 0.01)), osteope-
nia (T= 9 months, NT= 7 months, p= 0.04), and MI (T= 13 months, NT= 10 months, 
p= 0.04). CONCLUSIONS: Injectable testosterone therapy was shown to delay time 
to event for osteoporosis, osteopenia, and MI while not increasing the occur-
rence of stroke or MI. This study has shown that with long follow up injectable 
testosterone therapy delays the negative effects of hypogonadism in older men.
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OBJECTIVES: The association between rare genetic disorders, hereditary fructose 
intolerance (HFI) or alpha-1 antitrypsin deficiency (A1AT), and type 2 diabetes 
(T2D) has not yet been investigated. Therefore, the objective of this undertaking 
was to evaluate the association between both genetic disorders and T2D using 
four large observational databases and adjust for ascertainment bias. METHODS: 
Patients with a HFI diagnosis (ICD-9: 271.2) or A1AT diagnosis (ICD-9: 273.4) and 
T2D diagnosis (ICD-9: 250.x0 or 250.x2) were identified in the Truven MarketScan 
Claims Database (2007-2012), Optum Claims Database (2002-2012), Humedica 
Electronic Health Records (EHR) Database (2007-2012), and GE Centricity EHR 
Database (1995-2012). The association between both genetic disorders and T2D 
was compared to the association between T2D and seven negative control chronic 
diseases with no established relationship with T2D. RESULTS: The unadjusted 
association between both genetic disorders and T2D was positive and hetero-
geneous (p< 0.001) in all four databases. The unadjusted pooled odds ratio (OR) 
calculated using a random-effects model meta-analysis was 3.48 (95% CI: 2.21-
5.46) for HFI and 2.71 for A1AT (95% CI: 1.75-4.20). After pooling all patients and 
adjusting for the negative controls using a random-effects model meta-analysis, 
it was found that HFI patients have a 73% increased odds of T2D (ratio of odds 
ratios [ROR]= 1.73, 95% CI: 1.08-2.75) compared to patients with negative control 
diseases; the association was stronger when utilizing a fixed-effects model meta-
analysis (ROR= 2.19, 95% CI: 2.07, 2.31). The adjusted association between A1AT and 
T2D was statistically significant in the fixed-effects (ROR= 1.33, 95% CI: 1.27-1.40) 
model meta-analysis but not the random-effects model meta-analysis (ROR= 1.35, 
95% CI: 0.86, 2.12). CONCLUSIONS: HFI and T2D were positively associated after 
adjustment for negative control chronic diseases in both meta-analysis models. 
Rare disease researchers using observational data to conduct comorbidity analyses 
can utilize negative controls and multiple datasets to account for ascertainment 
bias and database heterogeneity, respectively.
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OBJECTIVES: Type 2 Diabetes(T2D) and its comorbid conditions are imposing large 
burdens on health-care systems worldwide. Once a patient is diagnosed with T2D, 
their risk for immediate chronic comorbid conditions is less quantified. We aim 
to build risk prediction models for onset of cardiovascular, cerebrovascular, renal 
and eye severe conditions for newly-diagnosed patients with T2D. METHODS: Our 
cohort includes 4.1million insurance beneficiaries of age≥ 18yrs between 2005 and 
2013. Of these subjects, 34,411 patients were newly-diagnosed with T2D, had con-
tinuous enrollment for 6months pre- and 5years post-onset, and did not have the 
comorbid condition diagnosis before T2D. We developed a prediction model for 
each condition based on L1-regularization method, which selects few(less than 
350 per condition) relevant risk factors from approximately 27K general variables 
derived from claims data. We defined comorbid conditions based on the validated 
diabetes complications severity index. RESULTS: For patients newly-diagnosed 
with T2D, we can predict new onset of cardiovascular conditions with Area Under 
Curve(AUC)= 0.69±1e-4; cerebrovascular conditions with AUC= 0.73±1e-4; renal com-
plications with AUC= 0.71±1e-4; eye conditions with AUC= 0.65±1e-4. Our method 
discovers risk factors, some of which have significant (p≤ 0.001) differences in odds 
ratios(OR) between genders/age subgroups. Top differences include: High albumin 
in blood for middle-aged patients(40≤ age< 65yrs) (male-OR 1.3[0.9-1.9] vs. female-
OR 2.1[1.5-3.4]) in cardiovascular events; High erythrocyte distribution width in old 
patients(age> 65) (male-OR 1.6[1.3-2.1] vs. female-OR 1[0.8-1.2]) in cerebrovascular 
events; High creatinine in middle aged patients (male-OR 4.6[3.4-6.0] vs. female-
OR 5.7[4.1-7.9]), high urea nitrogen for middle-age patients (male-OR 2.2[1.7-2.7] 
vs. female-OR 2.7[2.11-3.5]), and decreasing thyrotropin for old patients (male-OR 
1.1[0.9-1.5] vs. female-OR 0.6[0.4-0.7]) in renal events. CONCLUSIONS: Our proposed 
model shows promise in risk prediction and risk factor discovery for 4 comorbid 
complications of T2D in patients newly-diagnosed with T2D. Further research is 
needed to understand how these predictions translate to prevention and delay of 
the complications onset.
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performed to indirectly compare different strategies. METHODS: A pooled analysis 
of all available completed Novo Nordisk randomized clinical trials conducted in 
patients inadequately controlled on basal insulin (five trials) was used to com-
pare indirectly (1) IDegLira (N= 199) with (2) addition of liraglutide to basal insu-
lin (N= 225); (3) basal/bolus (BB) insulin (insulin glargine [IGlar] + insulin aspart) 
(N= 56); or (4) up-titration of IGlar (N= 329). All trials had comparable inclusion/
exclusion criteria, baseline characteristics and titration targets (in strategy 2 the 
basal insulin could not be up-titrated beyond baseline dose). Patient-level data 
were analyzed using multivariable statistical models with baseline heterogeneity 
accounted for using explanatory variables. RESULTS: For strategies 1–4, at end-of-
study (26 or 52 weeks) change in A1C (%) was –1.7, –1.3*, –1.4* and –1.0* respectively; 
change in body weight (kg) was –2.9, –3.5, +4.0* and +1.2*; mean daily basal insulin 
dose (U) was 37.8, 36.6, 62.4* and 60.7*; confirmed hypoglycemia rate (events/100 
patient-years) was 122.8, 124.4, 1060.8* and 286.1* (*p< 0.05 vs. IDegLira). Responder 
rates (percent of patients) were: with A1C < 7.0%: 64.7, 47.1*, 52.8 and 31.9*; with 
A1C < 7.0% and no hypoglycemia: 45.6, 35.5, 5.0* and 15.6*; with A1C < 7.0% and 
no hypoglycemia or weight gain: 39.1, 33.2, 0 and 7.7*. IDegLira was significantly 
better than strategies 3 and 4 for A1C reduction, weight reduction, insulin dose 
and hypoglycemia rate. Responder rates were greater with IDegLira versus strategy 
4. Results with IDegLira were similar (most endpoints) or better than those for 
strategy 2. CONCLUSIONS: These results suggest that IDegLira is more effective, 
with lower hypoglycemia rates, than up-titrated basal insulin or BB in patients 
uncontrolled on basal insulin.
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Bayesian network meta-analysis (nma) to assess relative efficacy 
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agonists in DUal anD triPle theraPy in Patients with tyPe 2 DiaBetes 
mellitUs (t2Dm)
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OBJECTIVES: To assess the relative efficacy of CANA, an inhibitor of sodium glu-
cose co-transporter 2, versus GLP-1 agonists, in second and third line for the 
treatment of T2DM patients, using NMA. METHODS: A systematic review of ran-
domized, controlled trials and Bayesian NMA were conducted to compare HbA1c 
lowering of CANA versus the GLP-1 agonists liraglutide and exenatide. NMAs 
were conducted separately by background treatment (metformin or metformin 
plus sulfonylurea) and trial duration (26/52/104 weeks). Networks were based on 
treatment- and dose-specific nodes. Non-informative priors were used. Relative 
efficacy was evaluated based on absolute differences in HbA1c reductions and 
Bayesian probabilities. RESULTS: In dual therapy, trials were identified reporting 
HbA1c reduction versus baseline at Weeks 26 (n= 8), 52 (n= 6), and 104 (n= 2). At 
Weeks 26 and 52, CANA 300/100mg had greater (Week 26: Δ = –0.17%/–0.28%) to 
similar (Week 52: Δ = –0.03%/0.09%) reductions versus exenatide 5µg, and lower/
similar versus exenatide 10µg (Week 26: Δ = 0.22%/0.10%). Reductions were greater 
for liraglutide 1.8/1.2mg, with differences versus CANA ranging between 0.20% and 
0.61%. At 104 weeks, reductions were similar for CANA 100mg (Δ = 0.04%/0.02%) 
and greater for CANA 300mg (Δ = 0.13%/0.11%) compared to liraglutide 1.2/1.8mg. 
In triple therapy, 5 trials reporting HbA1c reduction at Week 26 were identified 
to compare CANA versus liraglutide 1.8mg and exenatide 10/5µg. Reductions for 
CANA 100mg were similar to exenatide 5µg (Δ = –0.02%) and lower versus exena-
tide 10µg and liraglutide 1.8mg (Δ = –0.24% and –0.33%, respectively). Reductions 
for CANA 300mg were greater versus exenatide 5µg, and similar versus exenatide 
10µg and liraglutide 1.8mg (Δ = –0.01% and 0.08%). CONCLUSIONS: NMA results 
for dual therapy suggest increasing relative efficacy of CANA over time versus 
GLP-1 agonists, with CANA 300mg reaching similar HbA1c reductions as GLP-1 
agonists at 104 weeks. NMA results for triple therapy suggest at least similar 
efficacy for CANA 300mg.
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OBJECTIVES: Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 
is an effective and well-tolerated therapy in patients with type 2 diabetes mellitus 
(T2DM) in clinical trials. The objective of this study was to evaluate the impact of 
CANA on glycemic control in a real-world population. METHODS: A retrospective 
cohort analysis of adult patients with T2DM was conducted using 2013 data from 
the Inovalon MORE2 Registry, which consists of commercial, managed Medicare 
and Medicaid medical, pharmacy and laboratory claims. Patients with T2DM ≥ 18 
years of age with ≥ 60 days of canagliflozin supply and HbA1c test results within 120 
days pre- and ≥ 60 days post their first observed canagliflozin prescription fill were 
included. Patients with other types of diabetes, enrollment gaps and missing data 
were excluded. The difference between HbA1c levels pre- and post-canagliflozin was 
measured by a paired-t test. A subgroup analysis of patients with HbA1c> 7% at base-
line was also conducted. RESULTS: Of the 268 patients eligible patients with a claim 
for canagliflozin in 2013, 70% of patients received a 100mg dose. Median follow-up 
time to HbA1c measurement was 106 days. Mean (SD) age was 56.8 yrs (8.7), and 57% 
were male. The majority of the patients (63%) were covered by commercial payers. 
Mean HbA1c pre-canagliflozin was 8.3% (95% CI: 8.2%, 8.5%) and post-canagliflozin 
was 7.6% (95% CI: 7.5%, 7.8%). Mean difference in HbA1c pre-post was 0.7% (p< 0.001). 
In the subset of patients with HbA1c> 7% at baseline (81%), the mean difference 
pre-post canagliflozin was 0.9% (95% CI: 0.8%, 1.1%), p< 0.001. CONCLUSIONS: In a 
real-world setting, patients with T2DM had improved glycemic control as measured 
by HbA1c after receiving canagliflozin. HbA1c lowering in patients with baseline 
HbA1c> 7% was similar to the HbA1c improvement for all adults. The HbA1c results 
were generally similar to those observed in clinical trials.
socioeconomics, comorbidities and service year, patients receiving anti-diabetic 
medication were not associated with higher risk of dementia compared to non-
users (Odds Ratio [OR], 1.23; 95% confidence interval [CI], 0.94-1.62). We also found 
that exposure to specific anti-diabetic drugs were not related to the risk of devel-
oping dementia:metformin only (OR, 1.06; 95% CI, 0.69-1.64), sulfonylurea only (OR, 
1.04; 95% CI, 0.78-1.40), insulins only (OR, 0.77; 95% CI, 0.40-1.48), thiazolidinedione 
only (OR,0.77; 95% CI, 0.41-1.45). CONCLUSIONS: Use of anti-diabetic drugs, such 
as insulins, metformin, sulfonylurea and thiazolidinedione, are not associated 
with an altered risk of dementia among elderly.
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OBJECTIVES: Clinical studies suggest that adult type 2 diabetes (T2D) patients 
treated with the once-daily GLP-1 receptor agonist (RA) liraglutide 1.2 and 1.8mg 
achieve significant improvements in glycemic control and body weight with low 
risk of hypoglycemia. The objective of this study is to identify factors that predict 
clinical and economic outcomes associated with liraglutide therapy in a real-world 
setting. METHODS: Using the MarketScan® Laboratory Database, A1C outcomes and 
diabetes-related costs were evaluated in T2D patients initiating liraglutide (index 
event) between January 2010 and June 2012. Patients (N= 417) were required to have 
≥ 1 post-index claim for liraglutide and valid A1C values at baseline and within 
±45 days of the end of 6 months follow-up. Patients previously treated with GLP-1 
RAs or insulin, or evidence of type 1 diabetes, pregnancy or gestational diabetes 
at any time during the study period were excluded. Achievement of glycemic con-
trol (A1C < 7%) and diabetes-related costs were evaluated. Multivariable regression 
was used to identify significant (p< 0.05) predictors of glycemic control and to esti-
mate diabetes-related costs. RESULTS: Factors associated with increased odds of 
achieving A1C< 7% were early initiation (0-1 background oral anti-diabetics (OADs) 
vs. ≥ 2), adherence to liraglutide (proportion of days covered (PDC) ≥ 80%), pres-
ence of diabetic retinopathy or a disorder of lipid metabolism. Early initiation (0-1 
background OADs vs. ≥ 2) and higher out-of-pocket share of pharmacy costs were 
associated with significantly lower total diabetes-related costs at follow-up. Factors 
associated with significantly higher post-index total diabetes-related costs were 
higher baseline A1C, pre-index use of sulfonylureas, and the presence of diabetic 
retinopathy. The indicated impact of gender on clinical and economic outcomes, in 
this specific sample, varied by age. CONCLUSIONS: Predictors of glycemic control 
and diabetes-related costs among T2D patients treated with liraglutide in clinical 
practice include early liraglutide initiation, adherence, certain comorbidities and 
gender (age dependent).
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OBJECTIVES: In clinical trials, GLP-1 receptor agonists (GLP-1RA) dosed daily or 
once weekly (QW) have been shown to reduce HbA1c in patients with poorly 
controlled type 2 diabetes (T2D). However, little data exists on the real-world 
effectiveness of GLP-1RA in patients who have not attained HbA1c < 7.0% while on 
oral therapy. We evaluated glycemic response with GLP-1RA to inform decisions 
about initiating a GLP-1RA based on glycemic control. METHODS: This histori-
cal cohort study included adult T2D patients naïve to insulin and GLP-1RA in a 
national electronic medical record database initiating exenatide QW or liraglutide 
once daily between 2/1/2012 and 3/31/2013 (index date) with baseline HbA1c ≥ 7%. 
Changes in HbA1c from baseline to 6 months and 12 months were identified, as 
was the proportion with follow-up HbA1c < 7.0%. Outcomes were also assessed 
in patients with baseline HbA1c ≥ 9%. Paired t-tests and chi-square tests were 
used to test for significance of HbA1c change and proportion with HbA1c < 7% 
at follow-up. RESULTS: There were 1,474 patients initiating either exenatide 
QW (N= 376) or liraglutide (N= 1,098). Mean (SD) age was 57(11) years; 49.9% were 
female. Mean baseline HbA1c was 8.6%(1.4) overall and 10.2%(1.1) for the subset 
of 476 patients with baseline HbA1c ≥ 9%. At 6 months, mean HbA1c reduction 
was -0.9%(1.5) overall and -1.8%(1.8) in patients with baseline HbA1c ≥ 9% (p< .001 
for both). HbA1c reduction was similar at 12 months at -0.7%(1.5) overall and 
-1.5%(1.9) in patients with baseline HbA1c ≥ 9.0% (p< .001 for both). At 12 months, 
the proportion attaining HbA1c < 7.0% was 25.8% overall and 13% in patients with 
baseline HbA1c ≥ 9%. CONCLUSIONS: GLP-1RA treatment was associated with a 
significant reduction in HbA1c for up to 12 months in a real-world setting in all 
patients; results were more pronounced when baseline HbA1c ≥ 9%. GLP-1RAs may 
be considered in insulin-naïve patients with poorly controlled T2D.
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OBJECTIVES: IDegLira is a once-daily combination of insulin degludec (IDeg) 
and liraglutide. Trials directly comparing IDegLira with alternative strategies for 
intensifying basal insulin are ongoing. While awaiting results, this analysis was 
